# Alhemo®
# BILLING AND CODING GUIDE

Alhemo® concizumab-mtci injection | 60 mg | 150 mg | 300 mg pens

## Important Notice

Novo Nordisk Inc. has developed this reference guide to provide a list of codes that may be relevant for Alhemo®, a tissue factor pathway inhibitor antagonist, and its administration.[1] This information is current as of October 2025.

The information provided is intended for informational purposes only. These codes are not all-inclusive, and appropriate codes can vary by patient, setting of care, and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Novo Nordisk does not make any presentation or guarantee concerning reimbursement or coverage for any item or service.

## Coding for Alhemo®

### Current Procedural Terminology (CPT®) Codes[2]

| Administration CPT® code description | Code |
|---|---|
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 96372 |
| Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a physician or other qualified health care professional. | 99211 |

### Healthcare Common Procedure Coding System (HCPCS)[3]

| HCPCS code description | J Code |
|---|---|
| Alhemo® Injection, concizumab-mtci, 0.5 mg | J7173 |

## Indications and Usage

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with or without Factor VIII or IX inhibitors.

## Important Safety Information

### Contraindications

- Alhemo® is contraindicated in patients with a history of known serious hypersensitivity to Alhemo® or its ingredients

## National Drug Code[a] (NDC)[1]

| NDC 10-digit code[a] | Description[b] |
|---|---|
| 0169-2084-15 | 60 mg/1.5 mL (40 mg/mL) |
| 0169-2080-15 | 150 mg/1.5 mL (100 mg/mL) |
| 0169-2081-03 | 300 mg/3 mL (100 mg/mL) |

[a]Commercial payers may need an 11-digit code. This is created by adding a 0 to the beginning of the 10-digit code.
[b]Billable unit per mg or per pen package.

## Indications and Usage

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with or without Factor VIII or IX inhibitors.

## International Classification of Diseases, Tenth Revision, Clinical Modification[c] (ICD-10-CM)[4]

| Description | Code |
|---|---|
| Deficiency factor VIII (with functional defect) | D66 |
| Factor IX deficiency (with functional defect) | D67 |
| Symptomatic hemophilia A carrier | Z14.02 |

[c]The NDC and ICD-10-CM may be needed when the specialty pharmacy ships directly to the patient's residence.

HCPCS Modifier Note: As of January 1, 2024, Centers for Medicare & Medicaid Services (CMS) requires the use of the JZ modifier to indicate there were no units of a drug discarded/not administered to any patient. The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

## Important Safety Information (cont'd)

### Warnings and Precautions

- **Thromboembolic Events (TEs):** Venous and arterial TEs were reported in 1.9% of patients (6/320) who also had multiple risk factors, including the use of high doses or prolonged treatment with factor product or bypassing agent (2 of 6 patients). Risk factors for TEs may also include conditions in which tissue factor is overexpressed (eg, atherosclerotic disease, crush injury, cancer, disseminated intravascular coagulation, thrombotic microangiopathy, or septicemia). Inform patients about and monitor them for signs and symptoms of TEs. In case of suspicion of TEs, discontinue Alhemo® and initiate further investigations and management strategies
- **Hypersensitivity Reactions:** Alhemo® is contraindicated in patients with a history of known serious hypersensitivity to Alhemo® or its ingredients. Hypersensitivity reactions, including erythema, rash, pruritus, and abdominal pain, have occurred in patients treated with Alhemo®. One patient (<1%) experienced anaphylaxis, which resolved after treatment with antihistamines and corticosteroids. Instruct patients of the signs of acute hypersensitivity reactions and to contact their healthcare provider for mild reactions and to seek urgent medical attention for moderate to severe reactions. Discontinue Alhemo® if severe hypersensitivity symptoms occur and initiate medical management
- **Increased Laboratory Values of Fibrin D-dimer and Prothrombin Fragment 1.2:** Increased levels of fibrin D-dimer and prothrombin fragment 1.2 were seen in 29 (9.1%) and 26 (8.1%) patients, respectively, which is positively correlated with the plasma concentration of concizumab-mtci, indicating a hemostatic effect. For patients taking Alhemo®, these coagulation biomarkers may not be reliable predictive markers for clinical decision-making with suspicion of thrombosis, such as deep vein thrombosis and pulmonary embolism

## Important Safety Information (cont'd)

### Adverse Reactions

- The most frequently reported adverse reactions (≥5%) were injection site reactions, headache, and urticaria
- Serious adverse reactions were reported in 6.1% of patients with inhibitors who received Alhemo®. Permanent discontinuation of Alhemo® occurred in 1 patient due to a renal infarct and dosage interruptions of Alhemo® occurred in 1 patient (3%) and was a hypersensitivity reaction

### Drug Interactions

- **Breakthrough Bleeding Treatment:** Take appropriate precautions when treating breakthrough bleeding events in patients receiving Alhemo® prophylaxis and FVIII or FIX or a bypassing agent (eg, rFVIIa or aPCC). For mild and moderate bleeds, the lowest approved dose in the approved product labeling is recommended. For aPCC, a maximum dose of 100 units/kg within 24 hours is recommended. For severe bleeds, follow the dosing instructions in the approved labeling based on clinical judgment

### References


1. Alhemo® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
2. American Medical Association. CPT® 2025 Professional Edition. *American Medical Association*; 2024.
3. Data on file. Novo Nordisk Inc.; Plainsboro, NJ.
4. Centers for Medicare & Medicaid Services ICD-10 codes. Accessed August 18, 2025. https://www.cms.gov/medicare/coding-billing/icd-10-codes


**If you have additional questions on access and reimbursement of Alhemo®, please contact NovoCare® at 1-844-668-6732 or your Novo Nordisk field reimbursement manager.**

**Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536**



novo nordisk®